BioSpace News Archive

Intensity Therapeutics, Inc. today presented new data from the INVINCIBLE study in a live Spotlight Session Poster Presentation at the San Antonio Breast Cancer Symposium (SABCS) Annual Meeting being held at the Henry B. Gonzalez Convention Center, San Antonio, TX, from December 6-10, 2022.

Vizgen Launches MERSCOPE™ Formalin-Fixed Paraffin-Embedded (FFPE) Solution Kit.

Alnylam Pharmaceuticals, Inc. announced today that it will webcast its upcoming virtual R&D Day event on the Investors section of the Company’s website, www.alnylam.com, on December 15, 2022 at 8:30 am ET.

Can-Fite BioPharma Ltd. today announced progress achieved in the development of Piclidenoson for` the treatment of osteoarthritis in dogs by the Company’s veterinary commercialization partner Vetbiolix, which is covering all costs associated with veterinary clinical development.

Emergent Health Corp. announces it will be exhibiting at the 30th Annual A4M Winter World Congress December 9th - 11th at The Venetian Convention and Expo Center in Las Vegas.

Context Therapeutics Inc. announced preliminary Phase 2 data from the ongoing SMILE trial of onapristone extended release (ONA-XR), the company’s novel, first-in-class, potent, orally administered progesterone receptor (PR) antagonist, in metastatic breast cancer.

eSensei Biotherapeutics, Inc. today announced a streamlining and realignment of resources to support its key indications and programs, including its lead antibody, SNS-101, a conditionally active antibody targeting the immune checkpoint VISTA, as well as its other TMAb™ (Tumor Microenvironment Activated biologics) platform programs.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data were presented at the Virtual 33rd International Symposium on ALS/MND related to survival predictions from FORTITUDE-ALS.

Jounce Therapeutics, Inc. today reported new clinical data from the INNATE trial with JTX-8064 and pimi and the SELECT trial with vopra and pimi in two poster presentations at the ESMO-IO 2022 Annual Congress being held in Geneva, Switzerland.

HCW Biologics Inc. today announced that under a Cooperative Research and Development Agreement (CRADA), the National Cancer Institute (NCI) and HCW Biologics Inc. (HCW Biologics) will collaborate to perform a Phase 1b/2 clinical study to evaluate the safety and tolerability of HCW Biologics’ proprietary agent, HCW9218, in patients with advanced/metastatic pancreatic cancer.